A Drug-Drug Interaction, Safety and Efficacy Study With JNJ-56021927 (ARN-509) and Abiraterone Acetate in Subjects With Metastatic Castration-Resistant Prostate Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 05 Mar 2018
At a glance
- Drugs Apalutamide (Primary) ; Abiraterone acetate; Prednisone
- Indications Prostate cancer
- Focus Pharmacokinetics
- Sponsors Aragon Pharmaceuticals; Janssen Research & Development
- 27 Feb 2018 Planned End Date changed from 12 Jan 2018 to 30 Nov 2018.
- 27 Feb 2018 Planned primary completion date changed from 12 Jan 2018 to 29 May 2018.
- 10 Jun 2017 Biomarkers information updated